China NMPA Inspection - Fu'ermin (Hunan) Pharmaceutical Co., Ltd. - December 27, 2024

The National Medical Products Administration (NMPA) conducted a recent surprise inspection of Fu'ermin (Hunan) Pharmaceutical Co., Ltd., with the findings announced on December 27, 2024. The inspection revealed serious deficiencies within the company's production quality management system and significant non-compliance with regulatory standards. Specifically, Fu'ermin (Hunan) Pharmaceutical Co., Ltd. violated the "Cosmetics Supervision and Management Regulations" and the "Cosmetics Production Quality Management Standards."To protect public safety regarding cosmetic products, the NMPA has instructed the Hunan Provincial Drug Administration to initiate an investigation into the company's suspected illegal activities and enforce penalties. Consequently, Fu'ermin (Hunan) Pharmaceutical Co., Ltd. has been mandated to suspend all production and operation. The company is also required to rectify all identified issues to align its operations with national regulatory requirements, emphasizing the NMPA's commitment to stringent oversight in the cosmetics sector.